Teflaro, Zinforo(ceftaroline fosamil)
Teflaro, Zinforo (ceftaroline fosamil) is a small molecule pharmaceutical. Ceftaroline fosamil was first approved as Teflaro on 2010-10-29. It is used to treat escherichia coli infections, infectious skin diseases, klebsiella infections, pneumonia, and staphylococcal infections amongst others in the USA. It has been approved in Europe to treat community-acquired infections, infectious skin diseases, and pneumonia.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Teflaro (discontinued: Ceftaroline fosamil)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ceftaroline fosamil | ANDA | 2026-08-21 |
| teflaro | New Drug Application | 2024-11-20 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J0712 | Injection, ceftaroline fosamil, 10 mg |
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 3 | 2 | 8 | 4 | 16 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 2 | 1 | 7 | 4 | 2 | 15 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | 5 | 2 | — | 7 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 1 | 5 | 1 | 7 |
| Infectious skin diseases | D012874 | — | — | — | — | 4 | 1 | — | 5 |
| Communicable diseases | D003141 | — | — | — | 1 | — | 1 | 3 | 5 |
| Community-acquired pneumonia | D000098968 | — | — | — | — | 2 | 1 | 1 | 4 |
| Soft tissue infections | D018461 | — | — | — | — | 2 | 1 | 1 | 4 |
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | — | 2 | 1 | — | 3 |
| Surgical wound infection | D013530 | — | — | — | — | 2 | 1 | — | 3 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | — | 1 | 4 | — | 1 | 6 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | 4 | — | — | 5 |
| Wound infection | D014946 | — | — | — | 1 | 2 | — | — | 3 |
| Abscess | D000038 | EFO_0003030 | — | — | 1 | 2 | — | — | 3 |
| Bacterial skin diseases | D017192 | — | — | — | — | 2 | — | 1 | 3 |
| Staphylococcal infections | D013203 | — | A49.01 | — | — | 3 | — | — | 3 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | — | 1 | — | — | 2 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 1 | 1 | — | — | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gram-negative bacterial infections | D016905 | — | — | — | 1 | — | — | — | 1 |
| Gram-positive bacterial infections | D016908 | — | — | — | 1 | — | — | — | 1 |
| Toxemia | D014115 | — | — | — | 1 | — | — | — | 1 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Meningitis | D008581 | EFO_0000584 | G03 | 1 | — | — | — | — | 1 |
| Cerebral ventriculitis | D058565 | — | — | 1 | — | — | — | — | 1 |
| Cerebrospinal fluid shunts | D002557 | — | — | 1 | — | — | — | — | 1 |
| Ventriculoperitoneal shunt | D017287 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Retinal diseases | D012164 | — | H35.9 | 1 | — | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | — | — | — | — | 1 | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
| Inappropriate prescribing | D057970 | — | — | — | — | — | — | 1 | 1 |
| Skin diseases | D012871 | — | L00-L99 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Diabetic foot | D017719 | EFO_1001459 | — | — | — | — | — | 1 | 1 |
| Osteitis | D010000 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ceftaroline fosamil |
| INN | ceftaroline fosamil |
| Description | Ceftaroline fosamil acetate monohydrate is a hydrate that is the monohydrate form of ceftaroline fosamil acetate. A prodrug for ceftaroline, used for the treatment of adults with acute bacterial skin and skin structure infections. It has a role as an antimicrobial agent, an antibacterial drug and a prodrug. It contains a ceftaroline fosamil acetate. |
| Classification | Small molecule |
| Drug class | cephalosporins; phosphoro-derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 229016-73-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL501122 |
| ChEBI ID | 70718 |
| PubChem CID | 16007393 |
| DrugBank | DB06590 |
| UNII ID | 7P6FQA5D21 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Teflaro – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Teflaro – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 950 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
990 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use